Kestrel Therapeutics Inc. — Form D
Kestrel Therapeutics Inc. of Boston, MA, a company, filed a Form D exempt-offering notice with the SEC on 2025-02-21. The offering totals $16.0M, of which $8.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-02-21
- Form: D
- Accession: 0001853373-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $16.0M
- Amount sold: $8.0M
- Remaining: $8.0M
- Investors: 7
- Date of first sale: 2025-02-07
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-538994
Issuer
- Name: Kestrel Therapeutics Inc.
- CIK: 0001853373
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: Attn: Pagliuca Harvard Life Lab, Boston, MA, 02134
- Phone: 617-460-3772
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Nicholas G Saccomano | Director | Boston, MA |
| Denis G Patrick | Director | Boston, MA |
| Barbara G Sosnowski | Director | Boston, MA |
| Omar G Khalil | Director | Boston, MA |
| Andrew G Phillips | Director | Boston, MA |
| Frank G Haluska | Director | Boston, MA |
| Frank G Haluska | Executive Officer | Boston, MA |
Other filings by this issuer (3)
More